Zhengzhou university People's Hospital
Zhengzhou, Henan, 450000, China
NCT Number: NCT02642445
Renal sympathetic denervation from the intima of renal arteries has become an important method for the treatment of resistant hypertension, but renal sympathetic nerve are mainly located in the adventitia, and there is no report about renal sympathetic denervation from the renal adventitia. Primary aldosteronism is an important factor of secondary hypertension, tumor aldosterone in unilateral adrenal can increase the concentration of plasma aldosterone, in some patients blood pressure control is still not desirable after resection of tumor aldosterone. This study intends to conduct renal sympathetic denervation ablation from the adventitia to observe its efficacy and safety on blood pressure of patients with primary aldosterone.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Zhengzhou, Henan, 450000, China
Renal sympathetic denervation from the intima of renal arteries has become an important method for the treatment of resistant hypertension, but renal sympathetic nerve are mainly located in the adventitia, and there is no report about renal sympathetic denervation from the renal adventitia. Primary aldosteronism is an important factor of secondary hypertension, tumor aldosterone in unilateral adrenal can increase the concentration of plasma aldosterone, in some patients blood pressure control is still not desirable after resection of tumor aldosterone.
This study intends to conduct renal sympathetic denervation ablation(RDN)from the adventitia to observe its efficacy and safety on blood pressure of patients with primary aldosterone.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
Time frame: at 6 months,12 months,18 months
The Change of Systolic Blood Pressure from Baseline to 6 months,12 months, 18 months
Time frame: at 6 months,12 months,18 months
The Change of Renin from Baseline to 6 months,12 months, 18 months
Time frame: at 6 months,12 months,18 months
The Change of aldosterone from Baseline to 6 months,12 months, 18 months
Henan Institute of Cardiovascular Epidemiology
Other
Efficacy and Safety of Renal Sympathetic Denervation From The Adventitia on Hypertension in Patients With Primary Aldosteronism
Acronym: RSDAH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07700888
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Beijing, 李泽文, China
View Trial DetailsNCT03174847
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Singapore
View Trial DetailsNCT05361083
ACTH Syndrome, Ectopic, Adenocarcinoma
Uppsala, Sweden
View Trial DetailsNCT03990701
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Singapore
View Trial Details